Fatigue & insomnia
References
1 Tavee, J., & Sweeney, P. 07/15/2006. Alzheimer’s. www.clevelandclinicmeded.com/diseasemanagement/ http://www.clevelandclinicmeded.com/diseasemanagement/neurology/alzheimers/alzheimers.htm
2 Zhang, H., et al. 2004. Huperzine A enhances the level of secretory
amyloid precursor protein and protein kinase C-alpha in intracerebroventricular
beta-amyloid-(1-40) infused rats and human embryonic kidney 293 Swedish mutant cells.
Neurosci. Lett., 360 (1–2), 21–24.
Bai, D., et al. 2000. Huperzine A, a potential therapeutic agent for
treatment of Alzheimer’s disease. Curr. Med. Chem., 7 (3), 355–374.
Review.
Ved, H. et al. 1997. Huperzine A, a potential therapeutic agent for
dementia, reduces neuronal cell death caused by glutamate. Neuroreport, 8
(4), 963–968.
For more information or to join a study currently underway on huperzine
A (http://www.clinicaltrials.gov/show/NCT00083590) in Alzheimer’s disease,
visit the National Institutes of Health Clinical Trials webpage.
Further reading
For more information on Alzheimer’s, visit the following websites:
- National Institute on Aging: www.nia.nih.gov/alzheimers
- Alzheimer’s Association: www.alz.org
- Cleveland Clinic:
www.clevelandclinicmeded.com/diseasemanagement/
neurology/alzheimers/alzheimers.htm
Return to:
Alzheimer’s disease
Last Modified Date: 05/02/2011